ASCO 2024 | Biomarkers and Efficacy Analysis of Immunotherapy Combinations for Metastatic Prostate Cancer
The efficacy of endocrine therapy in advanced prostate cancer patients is poor, with most ultimately progressing to castration-resistant prostate cancer (CRPC). Although previous single-agent immunotherapies have shown limited success in prostate cancer, recent studies indicate that combination immunotherapies exhibit higher antitumor activity in patients with metastatic CRPC (mCRPC). At the recent ASCO Annual Meeting, a study analyzed the efficacy of different immunotherapy combinations for mCRPC patients and examined potential biomarkers.









